10-Q: Bioventus Inc. Reports Q3 2024 Results, Announces Divestiture of Advanced Rehabilitation Business

Bioventus Inc. announced its third quarter 2024 financial results, including a net loss, and the planned divestiture of its Advanced Rehabilitation Business.

Summary

• Bioventus Inc. reported a net loss of $5.4 million for the third quarter of 2024, compared to a net loss of $8.8 million in the same period last year.
• Net sales for the quarter were $139 million, up from $120.8 million in the third quarter of 2023.
• The company's U.S. segment saw a 15.7% increase in net sales, while the international segment increased by 10.2%.
• The company is divesting its Advanced Rehabilitation Business for $25 million at closing, plus up to $20 million in earn-out payments.
• The divestiture is expected to close near the end of 2024 or early 2025 and will be used to reduce long-term debt.
• Bioventus recorded a $33.9 million impairment charge related to the planned divestiture of the Advanced Rehabilitation Business.
• Adjusted EBITDA for the quarter was $23.6 million, compared to $21.7 million in the same period last year.
• The company's loss per share of Class A common stock was $0.07 for both basic and diluted shares.
• The company reclassified SonicOne revenue from Restorative Therapies to Surgical Solutions.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive revenue growth and strategic divestiture, the net loss, impairment charges, and litigation costs temper the overall sentiment. The company is taking steps to improve its financial position, but there are still significant challenges.

Positives

• Net sales increased by 15% year-over-year, indicating strong demand for the company's products.
• Adjusted EBITDA increased year-over-year, showing improved operational performance.
• The divestiture of the Advanced Rehabilitation Business is expected to simplify the company's structure and improve liquidity.
• The company received FDA clearance for its Allograft Delivery Device, which will support the growth of its OSTEOAMP product.
• The company received EU Certification for its Exogen Bone Stimulation System, allowing it to market the product throughout the EU.

Negatives

• The company reported a net loss of $5.4 million for the quarter.
• The company recorded a significant impairment charge of $33.9 million related to the divestiture of the Advanced Rehabilitation Business.
• The company incurred $13.7 million in shareholder litigation costs during the nine months ended September 28, 2024.
• Restructuring costs were incurred in the prior year, indicating past challenges in aligning the company's cost structure.

Risks

• The company might not realize all the benefits expected from the divestiture of the Advanced Rehabilitation Business.
• The company might not meet certain debt covenants under its Credit and Guaranty Agreement.
• The company is subject to securities class action litigation and may be subject to similar or other litigation in the future.
• The company is highly dependent on a limited number of products.
• The proposed down classification of non-invasive bone growth stimulators by the FDA could increase competition.
• The company faces pricing pressure and other competitive factors.
• The company relies on a limited number of third-party manufacturers.
• The company is subject to risks related to intellectual property matters.

Future Outlook

The company expects the divestiture of the Advanced Rehabilitation Business to close near the end of 2024 or early 2025, which is expected to simplify the business structure and improve liquidity. The company anticipates that current cash, cash equivalents, future cash flows from operating activities and cash available under its 2019 Credit Facility will be sufficient to meet its anticipated cash needs for at least 12 months from the issuance date of the financial statements.

Management Comments

• The company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body's natural healing processes.
• The divestiture of the Advanced Rehabilitation Business is expected to simplify the company's business structure and improve liquidity.
• The company believes that current cash, cash equivalents, future cash flows from operating activities and cash available under its 2019 Credit Facility will be sufficient to meet its anticipated cash needs for at least 12 months.

Industry Context

The medical device industry is characterized by ongoing innovation and regulatory changes. Bioventus's focus on minimally invasive treatments aligns with current trends in healthcare. The company's divestiture of the Advanced Rehabilitation Business and focus on core products is a strategic move to improve profitability and liquidity. The company's ability to obtain regulatory approvals, such as the FDA clearance for the Allograft Delivery Device and EU certification for the Exogen Bone Stimulation System, is critical for its growth and competitiveness.

Comparison to Industry Standards

• Bioventus's revenue growth of 15% in Q3 2024 is a positive sign, but it is important to compare this to the growth rates of its direct competitors such as Zimmer Biomet, Stryker, and Medtronic, which also operate in the orthopedics and medical device space.
• The company's adjusted EBITDA margin of approximately 17% (23.6/139) is a key metric to compare against industry benchmarks. Companies like Smith & Nephew and NuVasive, which have similar product portfolios, typically have EBITDA margins in the range of 20-30%.
• The impairment charge of $33.9 million related to the Advanced Rehabilitation Business divestiture is a significant event. It is important to assess how this compares to similar divestitures by other companies in the medical device sector. For example, when Medtronic divested its Physio-Control business, it also incurred significant charges.
• The company's debt leverage ratio and interest coverage ratio, as mentioned in the document, are important metrics to compare against industry averages. Companies with high debt levels may face challenges in a rising interest rate environment.
• The company's R&D spending of $10.4 million for the nine months ended September 28, 2024, is a key indicator of its commitment to innovation. This should be compared to the R&D spending of its competitors to assess its competitive position.

Legal Proceedings

• The company is involved in a putative class action lawsuit alleging violations of securities laws.
• The company is involved in multiple derivative shareholder lawsuits.
• The company is involved in a stockholder litigation related to the acquisition of Bioness.
• The company has reached a settlement agreement in the class action lawsuit, which is subject to court approval.

Stakeholder Impact

• Shareholders are impacted by the net loss, impairment charges, and litigation costs.
• Employees may be impacted by the divestiture of the Advanced Rehabilitation Business.
• Customers will benefit from the company's focus on core products and new product launches.
• Creditors are impacted by the company's debt obligations and financial covenants.
• Suppliers may be impacted by the company's strategic decisions and supply chain management.

Next Steps

• The company expects to close the divestiture of the Advanced Rehabilitation Business near the end of 2024 or early 2025.
• The company plans a limited launch of the Allograft Delivery Device in the fourth quarter of 2024.
• The company will continue to monitor and manage its debt obligations and financial covenants.
• The company will continue to defend itself vigorously in the ongoing shareholder litigation.
• The company will continue to focus on its core businesses and product development.

Key Dates

Keywords

Bioventus, Medical Devices, Orthopedics, Bone Graft, Pain Management, Surgical Solutions, Restorative Therapies, Divestiture, Impairment, EBITDA, Net Sales, FDA Clearance, EU Certification